Dane Leone
Stock Analyst at Raymond James
(1.58)
# 3,155
Out of 4,711 analysts
88
Total ratings
35.82%
Success rate
-6.21%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $1.28 | +212.50% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $7.62 | +490.55% | 2 | Feb 21, 2024 | |
| BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $90.14 | +10.94% | 9 | Dec 22, 2023 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $44.06 | -31.91% | 1 | Nov 16, 2023 | |
| BLUE bluebird bio | Maintains: Outperform | $200 → $260 | $8.50 | +2,958.82% | 6 | Nov 8, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $701.85 | +35.36% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.37 | +448.52% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $26.49 | +73.65% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $26.76 | +157.85% | 5 | May 8, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $4.16 | +597.12% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $8 | $1.38 | +479.71% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $29 → $14 | $8.50 | +64.71% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $24.13 | +140.36% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $28.58 | +144.93% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.87 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $48.87 | +28.91% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $57.33 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.08 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $52.91 | +22.85% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.61 | - | 5 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $263.38 | -3.18% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $5.75 | +456.52% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $144.47 | - | 2 | Jul 21, 2017 |
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $1.28
Upside: +212.50%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $7.62
Upside: +490.55%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $90.14
Upside: +10.94%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $44.06
Upside: -31.91%
bluebird bio
Nov 8, 2023
Maintains: Outperform
Price Target: $200 → $260
Current: $8.50
Upside: +2,958.82%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $701.85
Upside: +35.36%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.37
Upside: +448.52%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $26.49
Upside: +73.65%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $26.76
Upside: +157.85%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $4.16
Upside: +597.12%
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $1.38
Upside: +479.71%
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $8.50
Upside: +64.71%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $24.13
Upside: +140.36%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $28.58
Upside: +144.93%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.87
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $48.87
Upside: +28.91%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $57.33
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.08
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $52.91
Upside: +22.85%
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $5.61
Upside: -
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $263.38
Upside: -3.18%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $5.75
Upside: +456.52%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $144.47
Upside: -